October 2024 updates to prior authorizations and post service claim edits

Security Health Plan (SHP) requires prior authorization (PA) and post service claim edits (PSCE) on medications in order to ensure coverage and payment for those services. A number of requirements have been added for 2024 as we work to make sure all care, services and treatments are medically necessary. These drugs will be reviewed for medical necessity by Magellan.

Magellan will implement additional PA's & PSCE's October 1st, 2024, for the following drugs given in the office based and outpatient settings:

- Bkemv® (eculizumab-aeeb)
- Yesafili® (aflibercept-jbvf)
- Opuviz® (aflibercept-yszy)
- Imdelltra® (tarlatamab-dlle)
- Beqvez® (fidanacogene elaparvovec-dzkt)
- Hercessi® (trastuzumab-strf)
- Anktiva® (nogapendekin alfa inbakicept-pmln)
- Selarsdi® (ustekinumab-aekn)
- Rytelo® (imetelstat)

This is only the list of new prior authorizations and post-service claim edits required of members and providers to ensure payment for services. You can review the full list of all medications requiring a prior authorization and/or post-service claim edit on our website https://www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please get in touch with Security Health Plan Provider Relations at **1-800-548-1224.**